Treating Residual Tumor with capecitabine Boosts BC Survival

besa

http://www.medpagetoday.com/MeetingCoverage/SABCS/...

"Adjuvant capecitabine after incomplete response to neoadjuvant therapy"

""SAN ANTONIO -- When neoadjuvant therapy for early HER2-negative breast cancer left residual disease, additional chemotherapy after surgery led to significantly better survival, results of a large Japanese study showed.

Patients who received adjuvant chemotherapy with capecitabine (Xeloda) had a 5-year disease-free survival of 74.1% compared with 67.7% for patients who did not receive chemotherapy after surgery. Overall survival at 5 years was 89.2% with adjuvant capecitabine and 83.9% without....."

"

• Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
• When neoadjuvant therapy for early HER2-negative breast cancer left residual disease, additional chemotherapy with capecitabine after surgery led to significantly better survival than standard therapy.
• Note that subgroup analysis showed a consistent survival benefit in favor of adjuvant capecitabine, regardless of patient age, hormone receptor status, nodal status, pathologic grade, or type of neoadjuvant chemotherapy."